-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DHg2rfcTnNM2JdiYM/d9l8dbpu2vS8DrDM473bCOCnwywpKFLiFnScFl+A4eDRLs
 RVu3CXMeQWsBOuArop9lgg==

<SEC-DOCUMENT>0001193125-09-005299.txt : 20090113
<SEC-HEADER>0001193125-09-005299.hdr.sgml : 20090113
<ACCEPTANCE-DATETIME>20090113131413
ACCESSION NUMBER:		0001193125-09-005299
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20090109
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090113
DATE AS OF CHANGE:		20090113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADHEREX TECHNOLOGIES INC
		CENTRAL INDEX KEY:			0001211583
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32295
		FILM NUMBER:		09523453

	BUSINESS ADDRESS:	
		STREET 1:		4620 CREEKSTONE DRIVE
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
		BUSINESS PHONE:		919-484-8484

	MAIL ADDRESS:	
		STREET 1:		4620 CREEKSTONE DRIVE
		STREET 2:		SUITE 200
		CITY:			DURHAM
		STATE:			NC
		ZIP:			27703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:3px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="3"><B>Washington, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="5"><B>FORM 8-K </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="3"><B>the Securities Exchange Act of 1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>Date of Report (Date of earliest event reported) January&nbsp;9, 2009 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="6"><B>ADHEREX TECHNOLOGIES INC.
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"
ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>Canada </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(State or other jurisdiction of incorporation) </B></FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>001-32295</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>20-0442384</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Commission File Number)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(IRS Employer ID Number)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>4620 Creekstone Drive, Suite 200, Durham, North Carolina 27703 </B></FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="1"><B>(Address of principal executive offices) (Zip Code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
FACE="Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code (919)&nbsp;484-8484 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P
STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><FONT FACE="WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE> <P
STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:3px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P
STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;3.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. </B></FONT></TD></TR></TABLE> <P
STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">On January&nbsp;9, 2009, Adherex Technologies Inc. announced that Adherex has voluntarily filed to delist its common stock from NYSE Alternext US LLC
(formerly, the American Stock Exchange or &#147;AMEX&#148;). After receiving a notice from AMEX indicating that the Company failed to meet certain of the AMEX continued listing requirements, as previously announced by the Company on
December&nbsp;10, 2008, the Company&#146;s Board of Directors elected not to submit a plan of compliance and voluntarily file for delisting. The Board approved the voluntary delisting on January&nbsp;8, 2009 at its regularly scheduled Board meeting.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT FACE="Times New Roman" SIZE="2">A copy of the press release is attached as Exhibit 99.1 to this report and incorporated herein by reference. </FONT></P> <P
STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2"><B>Item&nbsp;9.01.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT FACE="Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Exhibits </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" ALIGN="center">

<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT FACE="Times New Roman" SIZE="1"><B>Exhibit&nbsp;No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT FACE="Times New Roman" SIZE="1"><B>Description of Document</B></FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Press Release dated January 9, 2009.</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
FACE="Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P> <P
STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0">

<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3"><FONT FACE="Times New Roman" SIZE="2"><B>Adherex Technologies Inc.</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT FACE="Times New Roman" SIZE="2">/s/ D. Scott Murray</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT FACE="Times New Roman" SIZE="2">Dated: January&nbsp;9, 2009</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">D. Scott Murray</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT FACE="Times New Roman" SIZE="2">Senior Vice President and General Counsel</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2">3 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT FACE="Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px">

<IMG SRC="g21986ex99-1_001.jpg" ALT="LOGO"> </P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>PRESS RELEASE </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman"
SIZE="2"><B>ADHEREX FILES TO DELIST FROM THE AMEX </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT FACE="Times New Roman" SIZE="2"><B>&#151; Stock Continues to Trade on TSX &#151; </B></FONT></P> <P
STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><B>Research Triangle Park, NC, January&nbsp;9, 2009</B> &#151; Adherex Technologies Inc. (AMEX:ADH, TSX:AHX), a biopharmaceutical company dedicated to solving problems
for patients with cancer, today announced that the Company has filed to voluntarily delist its common stock from the NYSE Alternext US LLC (formerly, the American Stock Exchange or &#147;AMEX&#148;). After receiving a notice from AMEX indicating
that the Company failed to meet certain of the AMEX continued listing requirements, as previously announced by the Company on December&nbsp;10, 2008, the Company&#146;s Board of Directors elected not to submit a plan of compliance and voluntarily
file for delisting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">To effect the delisting, the Company intends to file with the Securities and Exchange Commission a Form 25, Notification of Removal
from Listing and/or Registration, on or about January&nbsp;19, 2009. The Company expects that trading of its shares on the AMEX will be terminated on or about January&nbsp;29, 2009. Until the AMEX delisting becomes effective on or about
January&nbsp;29, 2009, the Company&#146;s common stock will continue to trade on the AMEX under the symbol &#147;ADH&#148;. The Company&#146;s stock listing will be noted with &#147;.BC&#148; after its trading symbol to reflect its non-compliance
with the AMEX listing requirements. The Company&#146;s common stock continues to trade under the symbol &#147;AHX&#148; on the Toronto Stock Exchange. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT FACE="Times New Roman"
SIZE="2"><B><I>About Adherex Technologies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Adherex Technologies Inc. is a biopharmaceutical company dedicated to the discovery and development of
novel cancer therapeutics. We are in the business of solving problems for patients with cancer.&nbsp;We have multiple products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS).&nbsp;Eniluracil, an oral
dihydropyrimidine dehydrogenase (DPD) inhibitor, is being developed to improve the tolerability and effectiveness of 5-fluorouracil (5-FU), one of the most widely used oncology drugs in the world. ADH-1 is a biotechnology compound which selectively
targets N-cadherin, a protein present on certain tumor cells and the blood vessels of solid tumors. STS is a chemoprotectant being developed to reduce or prevent hearing loss that may result from treatment with&nbsp;platinum-based chemotherapy
drugs. With a diversified portfolio of unique preclinical and clinical-stage cancer compounds and a management team with expertise in identifying, developing and commercializing novel cancer therapeutics, Adherex aims to become a leader in
developing innovative treatments that address important unmet medical needs in cancer. For more information, please visit our website at www.adherex.com. </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" COLOR="#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2"><I>This press release contains forward-looking statements that involve significant risks and uncertainties. The actual
results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. We are subject to various risks, including the adverse
impact of our stock no longer being listed on the AMEX, our need for additional capital to fund our operations, our history of losses, current and anticipated conditions in the economy and financial markets, our ability to continue to meet the
listing requirements of the Toronto Stock Exchange, the uncertainties of clinical trials, drug development and regulatory review, the early stage of our product candidates, our reliance on collaborative partners, and other risks inherent to the
biopharmaceutical industry. For a more detailed discussion of related risk factors, please refer to our public filings available at www.sedar.com and www.sec.gov.</I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
FACE="Times New Roman" SIZE="2"><B>For further information, please contact: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">D. Scott Murray </FONT></P> <P
STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Senior Vice President, Corporate Development </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">Adherex Technologies Inc.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">T: (919)&nbsp;484-8484 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT FACE="Times New Roman" SIZE="2">info@adherex.com </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g21986ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g21986ex99-1_001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+P"@`P$1``(1`0,1`?_$`,(```("`@,!`0$`````
M``````@)!PH!!0`$!@(#"P$``@$%`0$!````````````!P@&``($!0D#`0H0
M```&`0,#`@,#!P<-``````$"`P0%!@<`$0@A$@DQ$T$B%%%A%8&1,D(C%@IQ
M,W.T%R<8\*&QP7*S)#1$-55X.1$``0,"!0$&`P4$!`P'`````1$"`P0%`"$2
M!@<Q05%A(A,(<8$RD;$C%!6AP4)RT5*RL^&"PC-#-"5U%C<X"6*24S4F-A?_
MV@`,`P$``A$#$0`_`'D_Q'^17E<XO8/I,>_78.+IG`99P9JY5;K*QE)ILXLN
M`BB=,YT"OYYL)@WV[@+IL_9W9F5F_P"KN\@!90T"D$`C\4@!5_EPJ7NUN\E)
ML>DML3BV2LK2,BA2/KT^.*<))NRJ)JJIS$\HFW*@*RJ<E("DE[ZGLD]TP.-D
M@,K\I=_TC=`UTFECM$$S:=T<>IP"^5O]&.=OJ59S]23/_P`1_IP_W^'3R=(,
M.862*+)R;]PWO^"95RT;O'3AR09.G6R"D43D]Y4X%5_#I-V(B`;B4-*/[SK'
M%-L:U7*F:QL='7O:X@`*)`4Z#/-,-C[1[U+3;XK+1,YSC54BA23_`)I"47X8
MM^Y9S'B[!=*ELD9@N]=QY18,A!DK)9GZ3!BDLOL#=FW`W<N^D71@[46R!%%U
MA`0(0P[[<\;19KQ?KK%9[%3355PF5&1A>G?W#Q*##ZWF]VNP4K[K>YHJ>@B7
MS/*+\.\^&`4H7F(\=.1K4RIL%R.@XZ8E'R4=%+VRO6^GPD@\57*@@DG/V."C
MH9`%U#@4AEETBFWZ#HDW;@?EFQT)N=SM$QH@"28D>6A,]36DD$=O7`WM/.W%
MMZKFVZDN36U+I0T:P6J3T`)R0]F*9/DJGI8O/[ET1G.296H9PMOTY6TF\*W*
M@<S51+V027!(4C)G`Q1+\H@(;:Z/<"TE(>)K)JBC]7\F=2L"ZO4D55"KV8YW
M\UU4S.4+V8)'B$U3BU'J"#V@@HAP>G`B7FR>)7RPO@F94'K0F/S-'H2#SZMH
M86*`F,U<^_[S<Q@-U$A@T&N78(6\_P"QFM8P-,DBA`A_%[1T.#%Q%5U)X'WC
M)K<7-9&A)*A0?W81Z\OUY3:/3#=+@8`;.MP_>F;#;9(VPA_QN^^F_EM]`^*2
M:6"%S6229%K5S:[(9>&%8_5;FZ>&-L\K`1%_$Y#F.N>/Z"#+R%<.N-&),$5/
M.6?Z;4KJOAC%SQU6#K2=CL[4CJE0BQ7,O$UMA-2$:#DI^\IG14C*%^8-P'<>
M.\/%^_-YWNNJ-KV>KGHA65"O:C6`"4]"X@.SRR)3'6!O)FQMJ6:AIMPW2GCK
M110*U=3C^&WJ`J+XX,+!_(G"/)2J#>L&9)JN3*L1R9DZDJS(`X5CGX$`_P!#
M,QJQ4)6%>F2'N!%TBDH8OS``AUU#MQ;:W!M:N-HW#1S4M<`NF0(K>\$9'/N.
M)U8=SV+=5`+E8ZF.HH]63FN!0^(ZCYC'H\F9=QGA>L/;MEF^57'-1CS=CBP7
M&<CX"+(IVF.5NBN_52^I='*4>U%(#JG_`%2CK!M%GNU_J1;+%23U-6J!D8))
M[^G8.\Y8];Q>K1MVG-??:R*FI3VO*#X>)^&%ZO/-3XUFDL,1_B09+F*M[(R#
M*BY%=0_=N`=Y91&IF;*(]=^\HB40Z@.VBO'[>^79:83166?S=&ES`\]N0U8%
M4GN`XI%3^7==V%P**&NT_P#F3I@\<0Y]PSR!JA+KA7)%0R95O<*FK+U&;:RA
M&3@Q/<*VE&J9BOHA[V;C[+I))78-^W;0JW#MR^[>J76S<=)+15`R25I!_P`0
M]"?$*,%6R;AL6X*456WZJ&KC?_Z9#D)_K)FWYICRM_Y<<7,4V=Y2<E\@<04"
MXL$&3I_6+=?JY`SC-M(H%=,'#F,D'Z#I))\U."B1A*`'(("&ME:MD[NO]*+E
M:+?655`X('LC):K>I4#OQKKIO#:=AJ?T^ZW"DI:TYZ'O`/V''[U;E?QFNL#<
MK73<\XDM-9Q\R;RE[L$%?*V_AZ;'.@<?2OK+(H2!VD.V<`U5]LRQB>X)!`NX
M]->=PVENRTU45!7VRLCN%24C88W!TO\`*$4_)<7T&\-KW.DEKZ.XTDU!3_6]
MKP1'_,5R^:8]+A//>(>1M-/D+"=XA\ATDLW+5P+)!@Z&,5F8)8K>69MU7;9J
M=P#18X%]TA3)'WW(8P==8]^L-WVS<3:]PT[Z:X@`ECPC@#T4>.,JP[AM&Z*#
M]3LU0VHH22-3>BCKB9-:K&['3+'-5BL<U6*QS58K%07^)9NQW>4.+&-DE@,A
M!47(%W>(%W[06L-@AH%DH8-QV$R5<7V`?AI^?95:/3H;W?R/*Z:.GS[=/F_R
ML(=[P[L(KE9[2JNC@?*1XO.D%._R]<)%PQCH+5QCYIWXS85/[-(?CXX;JD*7
M9J6T9@+'N%!$`[B`=HV,`^G0=,GO2^NH>4-M6=I2.M-87`='!D*M4=J.(([B
M,+9M6R"OV/?[JYH+Z-E*A(4@OD0H4R4#-/G@BO#??1H/DAXUNC+>TUM4S;,?
M._FV(<EQILXQ9)#\-C2Z3;8!_6VU&/<[9'W?B*Z:,ORWIS_`1D%R=R@8EOMN
MO`M?+%O$A_UAKH<^^0$?OPR_^)4R+9%\H\:L2_7+)TUC0;-DD8Q,XE:O+1)6
M,*VVD7*0#LLXC(N+430$W\U]2KMU..@9[+['25-)==R$#\YZD433_$WR!YTG
MJ%7-.[!F]XEXK67"V6!A<*41.E<%*.5Q;F.A33VX1_POXGV7FKGZO8`JUJ@:
M7(62"M,VYL5A8/92/CHVK1"TD\(:-CSH.7RKS<B12`H0H=^XCL786GY6Y%I>
M,-H5.ZJZ"6H:R1C`QJHXR$?4.A1I7-<+7Q=L.JY$W=3[<HIFP3B-S];B1]()
MR3-<NS$7Y^QO>,.9IR7BC)4@66OF.+;)TVRRA';I^C(NX(Y639^U>/3"[79.
MXU-!1N*FQRH&(4P`(#J0[/O]EW18*7<&WF>G:*N!LD;4#0U1YP@R"/U`IV@X
MC>[K1<;!N*NLEU)=6TLIC<XE2[23YB3F2?'L3#>.`PB/B*\M6XB/[/'_`*]?
M^@;Z5_E[_J!V+_/)_>C#*<19<";R3^I']QPBM82E(<QR]P%!4Q@$"B`D*03'
M*/=TZE#TTX@9K+B$U"5V9Z`9K\SA2%<Z1K2N;&)GV]A^6"[Y9\4,I<7G.%IC
M*5CB+/)<@\0U[-$4\C'DG(/(YE,D30_`[`\E4R+.9J+:_3E.HD)T!(8"$'M(
M&AQQCR)8M^&ZPV"F--3VJO?3O;I:QKG@G4]H:@S*YHO?@D<@\?WC9D-NGOM0
M)Y+E0LGC.HN+6E$822N0^6#V\!V4K33_`"`5VBQ4@Z1JV7Z%>J_;8@JY_HGR
MU:@'5NKTHJ@&R8OHI[$'314V[R).E2[B!QT(O=MMJVU7&C]QMT&Z05L.AY`+
M@'![2W5UTE5(5%`P5?:KN.LMW(,5E:X_E*B"1I:2=)/E>"G11IR/C@8?)[RP
MR'RHY:98>VJ9D3T;'%XM./L6TP[E<(6K0-1EW->/)(1QCF;_`(_97<:=V]=F
M`5CBJ5,#`DF0H37@OC2U;)V'1S0-B?=:RC;4RRZ6ESI'A0QCB-6D*B+TQ"^<
MM^7S>&^ZREJ)7MME)5.A9&''00PD?2J$Y*2F//4K@M8KIP#RKSL0O<6RA\79
M+8T$V/3PZZLA+LU7=5CY&:_'@=II,E6SRVH"BV]A0%$DE!,<IA*`9]_Y:AM'
M+-NXO_(K/5TP?Z^LJR0M>Y`WM",<.O:,CC$M?%E37<7UG)3)F"*FJ-'II]04
M-/V%[<OF.F-#P$Y6WGB!R9QMD:IR\@VKTK:X"K91K2+A8D3<Z).RK6-EV4LR
M*;V'3R+2<`\8+F)[K9RB`E-VF,4?7F78-DW_`+$K[;<(!^O4T;I()-(UAX:2
MT:DU:2>H!Z8Q^'M[7?8V]*&KI)R+=/(ULL>HZ"PN`<K51?'!2^=9,@^2C+^P
M%-WTG#H`<2AW'`,?1(E.<1]>X#;ZAWM/;Z?$%,3GHJ*@GQ`D<TC$R]T,@=RS
M4/"^GZ$3D'<Z-IR'S7"MHO(5L@Z);L:1TNX8TR_3U4G[=%-53(IV![3D)EO6
MVLH!!#ZN.CG,ZLX30'<GU($4$!$A='&OL=FJKG#NJY01.JZ.E>R*21P#88G?
M6_/Z2$^H9A.N`Q0WRXTUEJ++1/>*>H(U-:2"Y.FH#ZD\<6_O"IR4P=@;@C`5
M7,.1(7']I=Y1R5-DKTXC+%F?P>3D6`Q<B9@TCG+A-H]3(8R9S@4#%`1#IOKD
M+[MN5>-F\PUPFO%`]@B@C'HR&5FJ-J.\S50KU.2XZ$^W"^V/;_%\5%=:AL%9
M^;ER<T@_PIV=,LL.NI_*_CC?H^7DZAF2D3;:`CG$O-$2F"-7T;%,4C+.Y)Q%
MOB-I,&39$@F44*B)2%ZCL&@;:]Y[6NK'RVZX4TM/&TEWF1P'P*%!\,,/1[BL
M=PA+Z>JB(CS)!3IWC&O1YC\5EA*!.0.*A$^W9O<HLH=OZ0"(G6*!=@^(CK%9
MR!LR8#T[G1^H7Z0"]"J]".JX\SNC;@D!%9"7NR34.OPQ.4Q;ZQ7:TZN4_8(N
M'JC)@65>V&1?MVT.UC5"D.F^6D#J?3$:*D.42G[NTP&#;UU)JJOHJ:A-=4S1
MLI6`$R+Y4[U[1GC<RSP4\7YF61K:9H743Y2#VK\\0D',#BZ98B!<^XM,N=4J
M1$26^*44.JH<$TTDP36-[AU#F`I0#<3"(`&HXS?FR9ZIM,RZ4?YLCRM]5H)^
M1_PXU+MRV"*1L1K*<F0Y><9_!,L4W//S=AM7D,G:^FJ"B..L38TJ@$3-N1%X
M_;2MQ?$,`"(`H(V9/?T'Y>NNMWM"M)I.)9*I$?5W)[R>_2`S_)QSH]U]S;7<
MFN@:=3*6EC9GV$^;[R?MQV^"N-R3_BF\LEG.T]Y48S$[5JKL4X[8Z<&OKM,I
M.T3`*97Z9Q'[-OLUK>7]PNM_/6R:</(])TP<-*D_F4B:I[E'RQE<66>.KX,W
MA6O;^,XPZ2J91NU#+PS(_9A6O&J\'QGR-P)D,JH(DIN9<:6)17O,D1-FRN,.
M=\)CE$H@F9B90#=0^41^&F*Y'M#;QL:^6N0:F3VV9H'7^$]%[N_`)X]N1M6\
M;57M\KXJ^(DC(IJ';^[#Q/XDXQ#\G^/9TQ`Q#X">F(8NP@8ALA39BF`0Z"`A
ML.E;]E<38]GWEJ9LN,:>'X;1]V7PPS/O`>'[IM+VE6NM[OF-;R/Z<##X$^OD
MAH(#U`V,LOAL/4/EK"9MA#TVZZG/NWD>.):B,$^G^>@R[%#P.GPQ"?:IYN6:
M<GZA23'Y^F[`R>5$`#R*<O-@`/[WGX]`VZC!00C^<1U*/;G_`,G;*.P4\G]]
M+B*>X$`<N7P#(>LS]L;"?M))/B<&UP&_^17EJ_H\?_U%#0FY>_Z@=B_SR?WH
MP4N(_P#D)O+^2/[CA$4D(@R=["(?L7(_E!(=A_E#3C-S$@[-9_M@?<3]N%-I
MP/S<?P9]XP^/S?=$/'2`=`'A14]P^`_]B]?M]=*)[4WO7=H4H;X\GQ4OZX:;
MW.M:(-K``(+)$F(-\'FP>2[`^_\`XC*@>@CU'&ME`/3TZCJ7^Z-H'$%6`,OS
M,']HXB'MF`=RU0KFC)?V1NPOGD&/=G_/(@/0<TY8_+M?[!Z_;U#1@V%_]#LX
M[66^/3X?AC(=V>!/O5Q_XRN))/\`[C-G_CG/!+83JOD0REQMLV),"TK.%^XQ
M6NV/%K36J+44Y^FR5RCU(-^]3?/DH]602D6ZT<P5,FFN4`%,@B&VH%NBX<+6
M;?,&Y=X5%%3[W@@!8^61P>T'4T%!X%P&62E,3?;=#RW>=GS;?VO!5U&TII_,
MUC`6.=D<BF1R"G'3@/'7SR:6"ONG/$'/R#5M8()TZ<*8]FBI(-V\LS6775,8
M@=J:*1!,8?0``=9-SYNXEGHIPR^44E0^%P`$CR7'20`%ZGN7%UHX<Y+@NE-/
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M5G)URD#]J0I2B8W40`!XM;`V8_>VYI+,YY@GEC,I<XEQZ9D]23AG=L[=9NNZ
M16L/$47I.>@R`<F;D'\7CB(YB/DZ#=9V'1?F;SE,LLU7QE8I11L;ZJ$D744Z
M6:J_(N#5T*!MR"/SIG$IMP$=16X4LFW[Q+%"XMDCD?&YS207:'%N9'4%,:1[
M);;434D#G-T2.84)&K2XMS3JJ8U3Z%>M&<5).V1DF%@;O7,4[!(`;/$F#Y2-
MD"("`%2$S)XF*:B8?H@)>FPE'7C6T553LIKDA%-4ND<U_;K!55[QCS=321-]
M81C\0#24Z$=2/'QP8=\YE7"\\3<?<;'H.@<UN7%"S6$ZPF"?IE?%-6C0IMSB
M=51FNMVN^\H`<K%`0$1,8`)M\Y9N-TXYI=ID2?G8I`)'J=3VCH''J<N_L3$M
MNV^*JZ;,@VZTO%5',-;US<P'H3U3OS1$Q)?C/XYAF/-B=[L$:DYH.'UV4XZ*
MY0]QM-7-P192L1'S#V*IQZB/X@N40,``@F4P;*==]P%LR7<FXS?JN)OZ702%
M%`(<7MZ9Y('%?EC>\8;>?=;R:VH8'VND:Y`X*TO=F,BH4$X0CY1+K^_WD)Y9
MV(BI7#5#*TC6(]P0VY#M*3%1%/)V#\>U2&.._I\VOTW\`6HV3B"R0`%OK4YF
M/BZ1Q<7'QS3X82?GFZ-NO*=VE8[4QM5H^3``!^S`KU8N:C4VSEHZ.5C8Z$K@
MUV_=!"Y'HQ@(Q`SG][C0A#5_]G'E`3_6CT0V$?DVU/[M#LPWB#]9%&V_-*P!
M[VZ\_P#-EJYA'JX`="<1*V0[F?9YS:Q4NL3D]<LU:/(=3M29?2@Q%RRJJ!!6
M0$4W*`F4;B3J)%T0%1$0#J'10@;?#?4BJX75<4M$YN4D;FEJJ"'-*M7M!Q&J
M"<4]>VH!\K'AP)[PX(?CA[GG2N2>1K7P6R(BH5=O>>&54LR;A,0,D=>7F32+
ME,I@Z&,DJ\$!^S?2C^U*F;:J;=5FS#J>[N:%ZHTZ6_L&&C]SM2ZX.VS=6N5L
M]HC<OQ'F_:3B-_`NJDAY'\>"LHDF*F-LO$2]U0B?NJ'JI.U%,#F+[BI@(8>T
M-Q[0$?0-;[W:,E=Q)4`!SI/SL#@F:A0J^"Y_%,:/VK3PQ<JP/D<UK/RDS27%
M,]+D3Q[,"=Y,;!#VGG]RUG(&1:RL2ZS-86[609*E7:.313=A#NS-UTQ,FNFD
M^8*I]Q1$HB0=A'4ZX#HJBW\3V:EJF&.<4A):0A&M[WA1WHX'$'YOKH+ERG>Z
MNE>)*=U0C7`J"&@-R^S!Y<!O_D5Y:OZ/'_\`44-!KE[_`*@=B_SR?WHP8>(_
M^0F\OY(_N.$127_)._Z%U_NATXS?])_.?[;<*=3?ZW'\&?>,/C\WW\SXZ?\`
MTHJ?^B"TH7M3^K=G^_'?>_#3^Y[_`#&U_P#<D>(:\%`B;R78<`=A`M6RV/7;
MI_=[.%`0W^(".I5[JG$<15(';64_]HG$8]L#6'E:E+AF()2/CI3[EPNWD.F=
M+D+GM!0ATUT<V9;*LBJ02*(G3R%8RB10@@`E.42]0'KHT<=>B=AVB5KA(W],
MA/P<&A3\<"7D!OI;VNS7L]-OZC,$'BX]^'_<1,EWS%'@+Y,WW&%RG*'>ZYG6
M5/$6JKR1XN<B%)&T8E8N?HWB(^ZW.[CW:B1M@W.FJ(?'?2?\A6JT[D]UUJME
MZ@CJ;34TX#XI&JQX$4[@#WHX!R^&&PX]OE?8?;+<KC9)9:>YP5(TR,<CFZI8
MAEW>50>W,X4A6/(MSYD+36(]3ESGQV#^SUY@9H:_2JI71'DPQ;&;&3'Y5`<%
M5$@E']+NVTPMXX6XBIK355`L%M9Z=.]VH1E6HTE0=79@$VGF/E2LNE/2.O5>
M\2S,;I,A(=J<`A'C@B_.L)R>27+GJ4W[AX<(8OQ`Q,=Q._7XB!M]1CVH0QMX
M;IXOJA_4*@M'8/Q'#+MZ8DGN@>ZJY5F,K4>REI]7Q,;"3\R<0=P_$2T:X;#M
MVVQ("_<`P[/<`W^W;7)G_NO/<_F+;K7$D?HDA^?J:?NRQX\0$_HM2.PSH?@G
M3#'<&9%ROBW(#>W862?+7IO$2C%N6.K)K:Y"*?%0+*"$.5H]$Q.Q,@&4]L03
M#XAOKF]L>\;GL^X([AM-FNYFF(/X9E)'<>Q,'.Q7*ZVNN%990XUX:@`"E#V)
MGCI3N/LR6&;F;#*8QR*M*3\O)3<HX2Q_9T$EY*6=J/WRI$BQ0$2*HZ7.($+T
M+\.FVL>OV[NZY54E77454ZHDD<]WX1^ISBYR>"G%\UHO]1*ZHFI*GU9'%SO(
M?J<5/[3@_3\=5++XU4;K8HUW3[UAG(-[LL<6RLW<$X>UF7EH=I,PBR$DBV<&
M-)@"2S+<NQW*(%+N!QT9IMD&KX/CJ[HWT;A;JN21NH(XM<?H_P`'A@EOVTZJ
MXU%94K37*DE<[41I<6K])7O"985:)]@[@*'IN!3'[2!L7N$#''T('V_9UTMS
M&F64LUZ3(`COZN:?L&6`S(`RH]-N1D8H/<2>OSZXMV<+\$PV!,!4:K,5F<C,
MS+%"X6Z;9G!5O+V2PLV[ITNU7*)BKQ[%J"#5J8!$#-T0-ZF'72KC3:]%M/:%
M+04>ESY8Q+(\?Z1SQJ4GM14^6'$V79(+!M^"E@(+Y&![W?UR[S9_`%/EBF]D
M?PZ>3O(5\NU[?<?V8/[G<;-:W8?VIXL,8%;%,O)4Y#&-;>IB"ZV_)KL'MWW'
M<)63;5!9&7.1L-'"(@/0ER`R`5/WXYX7[V\<O7?<%5=9K<QSYWEY/KQ9N/4K
MJ'7N1,6$/&[P5RM@WQQYPX_9BJ+2KY4S&[S8+V")-P\TD#:V4IM3*J#J3AWK
MR),*J#`I]O='VN_YA#;2<\P<EVC<_,=+O"Q3/DL](ZGTO0M($3]9\I`ZJ3Y@
M<SALN).-;MMWA^LVI>X&,NU6VHU,*%2]FEJG/N'0Y=1WXK=I>$3R7D23$_'Y
MH90$2`8H94Q;O[OM@4VP#:DP$H&$=MP#^33P4ONCX:B<V1]S>V7T0"/0E*/1
M#GISS^6$UD]M/+)'X=OC+#(<_4:#I50H+LOOPV_E'XK.2>>O'5P\8IU-HRY7
M\5Z+*T6=QRYLM?74MU(/)'03BH:SMG[FOJ3C-E"L'K--1R1)4%5D!.102Z6C
MCWG#:.R^5;W4ESI-A7FJ$C9F,(=&_2U7.:[S`&0O7Y'IAB-]\*;EW9QK9X-+
M&[RM-,Z(PN=Y7LUN+6L<"A(9I[?#KU25CSQ:>1VQW:.@8'C5E6D2AW@LOWML
MAF]$@H%,YA;NI)W;E)-`I&A$#F]P68K**);E*101[1:/<'/7"XM$E577.GJX
M0`13M9ZCW`=%"(">[).W"T;?X+Y7GN;*>CMM135)<097N,;&]A1V60Z9DJ<2
M#=?"]Y#H2V6*&KN`YVZ0D3+/(^,M[.R4%@RM+=JI[7X^Q9R=O1D6S&44*95`
MK@A5_:,45"E.)BAJ;=[F>(9J..HDN#*.1[`?2,,CBW+H=(0'L0998V%P]N/+
M4-7)$RVNG:"A>)8T=GF1J*GXX:=PU\>7,2A^.7R(X*N.&7]8RGFXM-2QC6I2
MSTS:SJ1C)(K\X2;.?>14<DW.7M$72R.X^F^EZY2Y:V%>N5]J[ILM>V:V6TN,
M[Q&]N@F0.'E<%<K<\@?MP?N,.*M[6;B_<NV+S1/AN%>&"%A>PZT:Y2H)1"0,
MT^':58._"%Y+U4'"8<?F!A416`I2Y4Q>(]YTS%*7K:R@7N'[1#3&2>Z;A)TT
MC([JC/,2D,J@]0J@]7#N[,`5OMJY8A$<WY`%X+<A(Q2`<USR0)ALOE-\;O,?
MDBGPQ)AK%;>TCB7B_7\=7T5;K283\%MS'\)!S$E"<GH\LB5+Z8_[=M[J)NWH
M;KI<_;WS1QYLJ3<7_$E:8F5UV?-"D4CM49)0^49=>W!YYTX@WSO&.PLL%+Z[
MJ*ULAE61C=+V]0I(4_#$=>)_Q=<V.,_-S'68\U8C;52@UZM9%9R4XG>Z)-G;
M/IVIR$3%I!&P-@D9%87+IT!-R)"4F_<80`-23W!<W<;;\XYFV]M:N?+=7U,3
M@WTGL&ENK42YP1`H/>J>.-+P1PKR#LS?T5\W!1LAM\<#QJ]1CLR@0!KB22">
MH1%\,2AY2/"/DK+66+=R/XCA`RDI?W2D[D/#TO*,ZX[5M2J9?Q*R4:9D3HPR
MH3ZJ(*NV#M1L(.S&425$#^V6-\">YVV[:L,.SM]A[*6G&B.IC!?I8/I:]H[.
M@U`$IU[SO^9O;==MPW^7=&RC&YTSC))"\AOG/5S2<L^J=G9A*)_&QY.XV.D,
M?(<:N0*5=E'[=W+5N-?LRTJ4DF@IE:R4@S86@]7?N6HI%%-PJ!SE`H;&Z!LS
MLO.G!=5717R6Z4;[DR/2V1].DK&H<@X,#A\1GV+A<&\.<T4E/)9&6RM_3W2*
MYC'DQ.*_40"APV#QK>#7,T/ERC9SY@Q412ZSCV;C;97<2(R\98[/;+-%N$GD
M$I;W$,N[@H*NQ+Y(CE5J19PZ=J)$3,"28G$P`YD]TMGK[%4;1X^)GJ*B)\<U
M4]A:!&\%KA&#EJ()`)`3JJC!VX>]LEUH[Y%N/?VB*"G>R6&!CE+I&.U`/[@H
M"A<^F-9Y9_&AS<Y)\X\D9;POA9>X8]GZQC>-B[$6X46'*Z=P5/814LE^'SMA
MC9%(&KY$Q-SI`!]MP$0V'7WV\\X\<[#XVI]O;CK6TMR9-,X@LDD^MQ(S&2YX
M\>>.'N0-X<AU%[L-"ZHM[XH@#K8`=`:.JA$3Y=JX"JD<4L^<3(]_3>0="6H-
MAM;[]YH%@K-UZ=+(PJ**44H\3=5R2DVB($>MS$]M0Y5=]A[=A`1YE?\`<MY`
MVIO_`)-L=[VE4"JH8[2^')CV#4JGZL_JSQ%MK;`W7L.EFI=R4AI!,[4Q7M?G
M_BK]^&J^*CKR[B0'T''=Z#](2[_LXD1]!#?;;\^E3]O#2[D#7$=$#:5R-4CL
M[ESP=N(6_P#R@E[07^@2IZ@IU`Z?LQXW+?-7E=!Y6R?!0V=+FQB87(=RBHI@
MA^!@DQC8^Q2;5BU3.I$*JF3;M4B$*)C&$0`-Q$=8&X>6M^T>Y:VCIKG,VECG
ME#6AL2`-D<`AT+D!WXP+UO[>%/=)88*Z1D0F>``UB`!Q``5G08UF7^8&1,I\
M;L>XEMMRE+99'5PLUOR',OS(%=.8YB_(WH=;<?2-F:*B#;99Z<O8("(([[CO
MMC;HY/O-_P!AT5DK*E\EP-1++4/(8-<>HZ&D-:!D#U`!/?BW<&^Z^\;7I[94
M2NDJG3.$Q1HU-&304`^T(?'`2G3/[8")3$(H"GM*'34]LXIB0J@IG`"E5]@Z
MA0-VC\HB`#L(Z$0IXG@5#VO93N8C6YHO7(]3]N!Z!,US:B5KB'!&KD``4`!R
M7IBR9XL.0O\`:5AM;$\^^%6WX>.C',`<*@=S)T!Z90:Z[*)Q$ZWX,L52/4$`
M^4B:/IW:>O@+>8W)MIUEJ7G]2MSM)!171NS:?@WIAIN,MPFYVD6JM=_M&G^T
MQG-O3L:$"X::!4=N@DV^XP>GW=='AT:JI=F5ZG!&'Y<#+0GRQ]A[>W3MV_)_
MEZ:^C2AZ)V_X<>^>2?+&-D]_4OYPU;Z8.8+D\"<424SZ8P)41`.I-M^GS`'7
MI]@Z^O:',\Y.@=<T'SQYD,5H*+_#W_+&!(EUW-\.NY_A^?7QHC.4:#OT_O3%
MR!H1V87MQCM0^TGH'ZP>FP;?'TVU>&D=I^W%KQ&3YT7QQ]%!'?Y>S?[C!O\`
MYAU:0P.\R:O''QOI`^72N,]I-Q'?X=0[NFW3X;ZH^FJG2N?=^W%VG,E2I3M[
MNB=V,=J77J7UZ_-\?OZ^NJTM<0A0IDA[/Z,6)"%73F<^G7^G'"E2`>@EW_VM
M_P#7K[I0%243M./K?17R:=7@F,]I/M#U'];\^W75,T:$C31X8O1%U*A[\8[4
MNWH)>W?<?F#M_D'KZ:N/U!?J[._Y8N8<_(B^&,@"8!L`EV'[P'\VOC0@1JIB
MU`"5Z]J_OQ@2D`!W'?H/J;?I]VX^FK"UA?J)S^.7V8N^IJ?PX67Y',(XES)5
MZHG8,O8SQ-E6MH2K^AK9$M]>K+*T12YVI9:">!+/VCX8Y1TDD9-T@14C5QMW
M%$#B&@?S'M7;FX[7'%7W*BMUXC+C3NJ)HV1O7J#K<%^2I@;\BV&TWNDC%36T
M]%<XQ^$Z61K`?#2YP#A]N*_D/2LMTZ^-&&/)`LC>D`>EB7F%KY`7:573*D<'
MRD0[Q],R<@HS49[BJ`D*`$_3#TTG3;5?-OWO_84K*NY%B+03LG.GO#8W.^W"
M\&VW>VUYFMD\<U?H1*63U':?!K"?M3&:5AVT9!EI!.2N6-:<9%>3<2TCDS*U
M!K#PSY(5EG34S"9L:$ZYF73X#)'*JB4`6,(J*$`##KRM^UJJ]S25=75V^FJ%
M.IM364\,JKG^&X@KWJ%7KBJ:QRW.4&HJZ2";M]>5D97Q!<"3W^.-E_AVNW9N
M6YX`$1#]`W)/"`%*8^P?,)+L(;D,&X[;]?MUE'8U4(W,97V0TV0+C<:8.T+Y
MB!J3Y]F,G_A*:.H<#7VDM!"%M7"5SS*$Y'P[,-8S5QTXV2'##&5,J&:,(I9)
MH;62EZE:7F4:%&1V0+4N=LKDF!)-NIQ*/<(.GSDA2F[S@R51;@?8!'=D]S[/
MV55<;4=JH;E:8KI31-=%,^I@T2',EFL/`D*Y`Y],%V^;=VS/M*GHH:V@960Q
M^20SQAKR<W(X.`<%)`([DP+7"+&6=<;\@ZC;*"MC&\D:IK,K]6Z3F_%-EE7E
M#DE&[&:=FBH2WO7@)Q:RJ+I(QD^P'"!"[@)PU`>)K#N2R[VAJ[7/;:V,Z6U#
M8*J)Q$94DZ&ESLB<R>G08B.R++=[5N>"KHIJ&J\FA[(ZECG>F2=3BT%Q"!$=
%V=F/_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
